Condition
Raynaud
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03941184Completed
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
NCT00822354Not ApplicableCompletedPrimary
Tadalafil for the Treatment of Raynaud's
NCT00498615Phase 3CompletedPrimary
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
Showing all 3 trials